nemolizumab treatment in patients with moderate-to-severe atopic dermatitis – post hoc analyses from the ARCADIA long-term extension (LTE) trial. Abstract #76707. Poster presented at 2026 AAD Annual Meeting; March 27-31, 2026; United States.

Reich A, et al. Long-term efficacy and safety of nemolizumab in adolescents with moderate-to-severe atopic dermatitis: Post hoc analyses from ARCADIA LTE two-year cut-off. Abstract #76688. Poster presented at 2026 AAD Annual Meeting; March 27-31, 2026; United States.

Silverberg JI, et al. Continuous response with nemolizumab - efficacy and safety up to 104 weeks in patients with moderate-to-severe atopic dermatitis with partial and minimal response (non-response) in skin at 16 weeks: post hoc analyses from ARCADIA LTE. Abstract #76623. Poster presented at 2026 AAD Annual Meeting; March 27-31, 2026; United States.

Chandrashekar BS, et al. A 12-week real-world evaluation of safety and efficacy of trifarotene treatment for fac
=*=*=*=*=*=
当前为第12/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页